Oorja Bio
Updated: August 29, 2026
Founders: Sujay Kango, Connie Coulomb, Janethe Pena
Country: USA | Funding: $30M (+)
Founded: 2023
Website: https://oorjabio.com/
Oorja Bio advances in-licensed, novel approach to treat idiopathic pulmonary fibrosis. The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining the structure and stability of the lungs. A lack of β1 integrin can promote inflammation and lung damage. β1 integrin is found on important skin cells in the lung’s air sacs, called alveoli. These alveolar type 2 cells secrete molecules that help the lungs expand easily when breathing and protect the balloon-like organs from infection. ORJ-001 was formerly called NP-201 and was discovered by a South Korean biotech called NIBEC.
Founded: 2023
Website: https://oorjabio.com/
Oorja Bio advances in-licensed, novel approach to treat idiopathic pulmonary fibrosis. The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining the structure and stability of the lungs. A lack of β1 integrin can promote inflammation and lung damage. β1 integrin is found on important skin cells in the lung’s air sacs, called alveoli. These alveolar type 2 cells secrete molecules that help the lungs expand easily when breathing and protect the balloon-like organs from infection. ORJ-001 was formerly called NP-201 and was discovered by a South Korean biotech called NIBEC.
